BREAST DUCTAL CARCINOMA IN SITU
Clinical trials for BREAST DUCTAL CARCINOMA IN SITU explained in plain language.
Never miss a new study
Get alerted when new BREAST DUCTAL CARCINOMA IN SITU trials appear
Sign up with your email to follow new studies for BREAST DUCTAL CARCINOMA IN SITU, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for tough breast cancer: drug aims to boost immune attack
Disease control TerminatedThis study tested the drug abemaciclib in 26 women with triple negative breast cancer that did not respond to standard chemotherapy. The goal was to see if the drug could increase immune cell activity in the tumor before surgery. The trial was stopped early, but results may help …
Matched conditions: BREAST DUCTAL CARCINOMA IN SITU
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 26, 2026 09:58 UTC
-
Hot flash drug studied in breast cancer patients – trial cut short
Symptom relief TerminatedThis study tested fezolinetant, a drug for hot flashes and night sweats, in women with breast cancer taking hormone therapy. The trial aimed to see if the drug could reduce the number and severity of these symptoms. Only 9 people took part before the study was stopped early.
Matched conditions: BREAST DUCTAL CARCINOMA IN SITU
Phase: PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Symptom relief
Last updated May 26, 2026 09:53 UTC